Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1155 - 1158
Section III - Un futur en développement
DOI https://doi.org/10.1051/medsci/200925121155
Publié en ligne 15 décembre 2009
  1. Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22 : 238–44. [Google Scholar]
  2. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314 : 628–31. [Google Scholar]
  3. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab’ gamma)2 antibody containing thioether-linked Fab’ gamma fragments. J Immunol 1987; 139 : 2367–75. [Google Scholar]
  4. Behar G, Sibéril S, Groulet A, et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008; 21 : 1–10. [Google Scholar]
  5. Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9 : 319–26. [Google Scholar]
  6. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321 : 974–7. [Google Scholar]
  7. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363 : 446–8. [Google Scholar]
  8. Willems A, Schoonooghe S, Eeckhout D, et al. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation. Cancer Immunol Immunother 2005; 54 : 1059–71. [Google Scholar]
  9. Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25 : 1290–7. [Google Scholar]
  10. Baeuerle PA, Reinhardt C, Kufer P. BiTE : a new class of antibodies that recruit T-cells. Drugs of the Future 2008; 33 : 137–47. [Google Scholar]
  11. Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates : enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989; 30 : 1358–66. [Google Scholar]
  12. Goldenberg DM, Chatal J, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007; 2 : 19–31. [Google Scholar]
  13. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008; 49 : 158–63. [Google Scholar]
  14. Robert B, Dorvillius M, Buchegger F, et al. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int J Cancer 1999; 81 : 285–91. [Google Scholar]
  15. Dorvillius M, Garambois V, Pourquier D, et al. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens : ErbB-2 and carcinoembryonic antigen. Tumour Biol 2002; 23 : 337–47. [Google Scholar]
  16. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99 : 1415–25. [Google Scholar]
  17. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280 : 19665–72. [Google Scholar]
  18. Qu Z, Goldenberg DM, Cardillo TM, et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111 : 2211–9. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.